Menin inhibitors are drugs that target the menin protein, crucial for regulating gene expression. The future of menin inhibitors is promising, with potential applications in treating various types of cancer.

Sana Biotechnology Releases Initial Clinical Findings Demonstrating SC291, an Off-the-Shelf CAR T Treatment Targeting CD19, Remains Undetected by a Functional Immune System.

In the CAR-T field, we can perform comprehensive data retrieval of CAR-T in two major parts: antibody search and CAR expression cassette design.

Benitec Biopharma has reported initial dosing in an early-stage trial for its genetic treatment prospect, BB-301, aimed at tackling Oculopharyngeal Muscular Dystrophy.

Nrf2 inhibitors are compounds that target the Nrf2 transcription factor, crucial for defense against oxidative stress.

Ambrx Reports Progress on APEX-01 Trial, a Phase 1 / 2 Study Assessing Increasing Doses of ARX517, Its Own PSMA-Directed Antibody-Drug Conjugate, in Advanced Prostate Cancer Unresponsive to Hormonal Therapy.

Myostatin inhibitors are drugs that target myostatin, a protein that regulates muscle growth. The future of myostatin inhibitors is promising, with potential applications in treating muscle-wasting conditions.

uniQure N.V., a leader in gene therapy, has announced FDA approval of its IND application for AMT-191 to treat severe medical conditions.

mTOR inhibitors are drugs that target the mTOR protein kinase, crucial for regulating cell growth and survival.

BioVie Inc., a biopharmaceutical firm focusing on neurological, neurodegenerative, and severe liver diseases, reported positive initial results from its Phase 3 trial of NE3107 in mild to moderate Alzheimer’s patients.

Somatic cell gene therapy targets those cells of the body that are not involved in reproduction – the somatic cells.

Carisma Therapeutics Inc. has confirmed that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for their novel product, CT-0525.